Elevance Health, Inc.
No SEC Form 4 filings for $ELV in the last 30 days.
See all $ELV insider activity →AM Best withdrew the ratings of WellPoint Insurance Services, a captive of Elevance Health, at the company's request. The ratings were affirmed as 'A- (Excellent)' with a 'stable' outlook, reflecting adequate balance sheet strength, operating performance, and risk management. Elevance Health's financial strength supports the captive, with planned capital growth and no dividends to the parent.
The Trump administration plans to remove 750,000 ACA enrollees due to alleged fraud, saving $2.2B. Affected individuals include those unaware of enrollments, high earners, and those with employer-provided healthcare. Leading ACA marketplace operators traded lower on the news.
Louisiana's Department of Health proposed $16.1B in contracts for four remaining Medicaid insurers: Aetna, AmeriHealth, Humana, and Louisiana Healthcare. This follows the exit of UnitedHealthcare and Elevance Health's Healthy Blue, affecting 580K enrollees. The contracts range from $3.2B to $5.8B annually, pending legislative approval.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ELV (Elevance Health, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent ELV coverage spans earnings, regulation and corporate actions.
Rating withdrawal may slightly increase perceived risk of the captive, but Elevance's strong balance sheet mitigates broader impact.
Potential negative impact on Elevance Health earnings.
Elevance gains significant Medicaid revenue, offsetting other plan exits.
Potential loss of Medicaid revenue and increased operational costs for transition.
Price move reflects valuation perception; no immediate catalyst beyond valuation metrics.
AlphAI scores every news story that mentions ELV with an AI model for sentiment and relevance, and aggregates insider trades from Elevance Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
AM Best withdrew the ratings of WellPoint Insurance Services, a captive of Elevance Health, at the company's request. The ratings were affirmed as 'A- (Excellent)' with a 'stable' outlook, reflecting adequate balance sheet strength, operating performance, and risk management. Elevance Health's financial strength supports the captive, with planned capital growth and no dividends to the parent.
1 min readThe Trump administration plans to remove 750,000 ACA enrollees due to alleged fraud, saving $2.2B. Affected individuals include those unaware of enrollments, high earners, and those with employer-provided healthcare. Leading ACA marketplace operators traded lower on the news.
2 min readLouisiana's Department of Health proposed $16.1B in contracts for four remaining Medicaid insurers: Aetna, AmeriHealth, Humana, and Louisiana Healthcare. This follows the exit of UnitedHealthcare and Elevance Health's Healthy Blue, affecting 580K enrollees. The contracts range from $3.2B to $5.8B annually, pending legislative approval.
2 min readElevance Health's Healthy Blue will exit Louisiana's Medicaid market by Jan. 1, 2027, affecting 290,000 enrollees. The state will facilitate a special enrollment period for affected individuals to choose among four remaining insurers. Healthy Blue did not disclose reasons for its departure, but reports suggest Elevance Health is downsizing Medicaid operations in several states due to weak profit margins.
2 min readElevance Health Inc (ELV) shares rose 5.0% to $416.54 on September 10, 2026. The stock is 13.8% below its estimated fair value of $483.43, according to GF Value™. The company's GF Score™ is 90/100, with strong ratings in profitability and growth. Insiders have shown net buying of $0.5M over the past 12 months. The P/E ratio is 18.5x, slightly above its 5-year median of 17.9x.
2 min readElevance Health (ELV) stock rose 5.8% to $418.21 after reaffirming its 2026 adjusted earnings guidance of at least $27.00 per share and signaling Q3 EPS is tracking ahead of expectations. The company also maintained its 2026 operating cash flow target of $6 billion and a 12% adjusted EPS growth target for 2027. Today is the ex-dividend date for its $1.72 per share quarterly dividend.
2 min readElevance Health reaffirmed its 2026 benefit expense ratio guidance at 90.2% (+/- 0.5%), indicating stable medical utilization and specialty pharmacy costs. The company expects to meet its adjusted earnings guidance of at least $27 per diluted share. Q2 2026 results showed an 89.7% ratio, up 0.8% YoY, driven by government business costs. Elevance, the second-largest US health insurer, processes pharmacy claims through Carelon. Steady ratio signals heavy claims payouts, impacting fall renewals.
2 min readElevance Health (ELV) stock surged after CMS finalized a 2.48% Medicare Advantage payment rate increase for 2027, above expectations. Evercore ISI reinstated ELV with an 'Inline' rating, questioning if the bounce is priced in. The company offers health plans, specialty insurance, and pharmacy services.
2 min readElevance Health (ELV) reaffirmed its 2026 earnings guidance, expecting at least $20.10 per diluted share, including $6.90 in net unfavorable items, and adjusted earnings of at least $27.00 per share. The company also maintained its benefit expense ratio target of 90.2% plus or minus 50 basis points. This reaffirmation aims to reduce uncertainty around full-year expectations.
1 min readElevance Health (ELV) reaffirmed 2026 EPS guidance and expects at least 12% EPS growth in 2027, citing strong segment performance and AI investments. Medicare Advantage, Medicaid, and ACA segments are outperforming expectations, with improved rate environments and cost initiatives supporting margins, according to management at the Wells Fargo Healthcare Conference.
1 min read
